These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22067789)

  • 1. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.
    Blode H; Klipping C; Richard F; Trummer D; Rohde B; Diefenbach K
    Contraception; 2012 Feb; 85(2):177-84. PubMed ID: 22067789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
    Wiesinger H; Eydeler U; Richard F; Trummer D; Blode H; Rohde B; Diefenbach K
    Clin Drug Investig; 2012 Oct; 32(10):673-84. PubMed ID: 22909145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
    Bart S; Marr J; Diefenbach K; Trummer D; Sampson-Landers C
    Contraception; 2012 Jan; 85(1):42-50. PubMed ID: 22067790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.
    Rapkin RB; Creinin MD
    Expert Opin Pharmacother; 2011 Oct; 12(15):2403-10. PubMed ID: 21877996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
    Chaiyasit N; Taneepanichskul S
    J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H; Schürmann R; Benda N
    Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
    Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyaz®: an oral contraceptive fortified with folate.
    Fruzzetti F
    Womens Health (Lond); 2012 Jan; 8(1):13-9. PubMed ID: 22171769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
    Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
    Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
    Oner G; Muderris II
    Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drospirenone: high risk of venous thrombosis.
    Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone.
    Zimmerman Y; Wouters W; Coelingh Bennink HJ
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):206-14. PubMed ID: 23550808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
    Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
    Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
    Batukan C; Muderris II
    Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
    Koltun W; Maloney JM; Marr J; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.